Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1725-1730

  Li, Chonghua ^a   Du, Xiaoli ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; ERADICATION THERAPY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT RESPONSE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; THIENAMYCINS;

EID: 34248328649     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00294-06     Document Type: Article

References (20)

1. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Strepto coccus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
2. Ariano, R. E., A. Nyhlen, J. P. Donnelly, D. S. Sitar, G. K. Harding, and S. A. Zelenitsky. 2005. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann. Pharmacother. 39:32-38.
3. Colardyn, F., and K. L. Faulkner. 1996. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J. Antimicrob. Chemother. 38:523-537.
4. Dreetz, M., J. Hamacher, J. Eller, K. Borner, P. Koeppe, T. Schaberg, and H. Lode. 1996. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob. Agents Chemother. 40:105-109.
5. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36:S42-S50.
6. Du, X., C. Li, J. L. Kuti, C. H. Nightingale, and D. P. Nicolau. 2006. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J. Clin. Pharmacol. 46:69-75.
7. Fish, D. N., and T. J. Singletary. 1997. Meropenem, a new carbapenem antibiotic. Pharmacotherapy 17:644-669.
8. Food and Drug Administration. 1999. Guidance for industry: population pharmacokinetics. Food and Drug Administration, Rockville, MD.
9. Krueger, W. A., G. Neeser, H. Schuster, T. H. Schroeder, E. Hoffmann, A Heininger, H. J. Dieterich, H. Forst, and K. E. Unertl. 2003. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 49:280-286.
10. Li, C., J. L. Kuti, C. H. Nightingale, and D. P. Nicolau. 2006. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. 46:1171-1178.
11. Lowe, M. N., and H. M. Lamb. 2000. Meropenem: an updated review of its use in the management of intra-abdominal infections. Drugs 60:619-646.
12. Manduru, M., L. B. Mihm, R. L. White, L. V. Friedrich, P. A. Flume, and J. A. Bosso. 1997. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 41:2053-2056.
13. Mouton, J. W., and J. G. den Hollander. 1994. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38:931-936.
14. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.
15. Sieger, B., S. J. Berman, R. W. Geckler, and S. A. Farkas. 1997. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Crit. Care Med. 25:1663-1670.
16. Tam, V. H., P. S. McKinnon, R. L. Akins, M. J. Rybak, and G. L. Drusano. 2002. Pharmacodynamics of cefepime in patients with Gram-negative infections. J. Antimicrob. Chemother. 50:425-428.
17. Tam, V. H., A. N. Schilling, S. Neshat, K. Poole, D. A. Melnick, and E. A. Coyle. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920-4927.
18. Turnidge, J. D. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22.
19. Walker, R., D. Andes, J. Conklin, S. C. Ebert, and W. Craig. 1994. Abstr. 34th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-91.
20. Wiseman, L. R., A. J. Wagstaff, R. N. Brogden, and H. M. Bryson. 1995. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73-101.